Eagle’s Eye View: Weight Reversal Post Tirzepatide Withdrawal
In this week’s View, Dr. Eagle looks at the DANISH trial extended follow-up, evaluating which patients benefit most from primary prevention implantable cardioverter defibrillator (ICD) implantation. He then explores the SURMOUNT-4 study on weight reversal post tirzepatide withdrawal. Finally, Dr. Eagle examines two JACC articles that cover disease monitoring: one tracking the progression of transthyretin amyloid cardiomyopathy (ATTR-CM) and another assessing cardiovascular risks in patients receiving cancer therapy.
X Links:
- Kim Eagle, MD, MACC keaglemd
Clinical Topics: Arrhythmias and Clinical EP, Cardio-Oncology, Cardiovascular Care Team, Heart Failure and Cardiomyopathies, Prevention, Implantable Devices, SCD/Ventricular Arrhythmias, Acute Heart Failure, Diet, Acute Coronary Syndromes
Keywords: Defibrillators, Implantable, Death, Sudden, Cardiac, Primary Prevention, Heart Failure, Heart Disease Risk Factors, Obesity, Anti-Obesity Agents, Weight Gain, Obesity Management, Weight Loss, Fasting, Quality of Life, Disease Progression, Cardiomyopathies, Amyloidosis, Myocarditis, Vascular Endothelial Growth Factor A, Cardiotoxicity, Immune Checkpoint Inhibitors, Protein-Tyrosine Kinases, EaglesEyeView
